Drug Modeling Software Market size is expected to reach USD 11,299.85 Million By 2027, Rising At a Market Growth of 8.1% CAGR During The Forecast Period

The insight partners adds "Drug Modeling Software Market forecast to 2027 - covid-19 impact and global analysis" to its store providing analysis of the current and future market competition in the market. Insightful review of the key Market drivers, opportunities, barriers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Request sample pages of this research study at - https://www.theinsightpartners.com/sample/TIPRE00013619/?utm_source=OpenPR&utm_medium=10366

The drug modeling software market was valued at US$ 6,205.22 million in 2019 and is projected to reach US$ 11,299.85 million by 2027; it is expected to grow at a CAGR of 8.1% from 2020 to 2027.

Drug modeling has become an essential tool in the drug design process. Software based drug discovery and development methods are playing a key role in the development of novel drugs. Software based methods such as molecular modeling, structure-based drug design, structure-based virtual screening, ligand interaction, and molecular dynamics are considered to be powerful tool for the investigation of pharmacokinetic and pharmacodynamic properties of drugs. These methods are fast, accurate, and provide valuable insights of experimental findings and mechanisms of action. Additionally, appropriate implementation of these techniques may help in reducing drug designing and development cost. Increasing cost of the drug development coupled with increasing drug failures is likely to drive the growth of the drug modeling software market during the forecast period. However, the market is likely to get negatively impacted by the less adoption of drug modeling software in emerging countries.

Order a copy of this research study at -

https://www.theinsightpartners.com/buy/TIPRE00013619/?utm_source=OpenPR&utm_medium=10366

Product Type-Based Insights

Based on product type, the drug modeling software market is segmented into database, software, and others. The software segment held the largest share of the market in 2019. Successful drug discovery, development, and launch of a single new drug into the market, costs about one billion dollars, and it requires nearly 12 years for accomplishing. High cost, insufficient and lengthy-time duration, high level of risk, uncertainty in the results, and highly complex procedures are the main challenges in developing a new drug. To overcome these problems, there is a strong need to employ new and cost-effective drug discovery and designing methods, such as software and computer-aided drug design and molecular docking. For instance, the platform provided by Schrödinger has devoted decades to refining computational algorithms to accurately compute the essential properties of molecules. The company uses NVIDIA GPUs to generate and evaluate the petabytes of data to accelerate drug discovery, as an improvement over the traditional process of slow and expensive lab work.

Exploring software and model-based tools has become a vital way of drug discovery and development in the pharmaceutical industry, playing a crucial role in expanding new bio-active drugs across a range of therapeutic areas. Proper use of software and computer-based modern methods has reduced several hindrances in drug discovery and hastened new drug development.

Application-Based Insights

Based on application, the drug modeling software market is segmented into drug discovery and development, medical imaging, computational physiological medicine, predictive analysis of drug targets, disease modeling, simulation software, cellular simulation, and others. The drug discovery process is complex and includes an interdisciplinary effort to design practical and commercially feasible drugs. In pharmaceutical, medicinal, and  other scientific research, a computer plays a significant role in the development of new compounds in the quest for better therapeutic agents.

Moreover, computational power along with advanced analytical techniques such as X-ray crystallography and NMR, have improved the application of CADD (Computer-Aided Drug Design) in the field of pharmaceutical industries like numerous of approved drugs that credited their discovery in large part to the tools of CADD, such as angiotensin-converting enzyme (ACE) inhibitor captopril for the treatment of hypertension, Carbonic anhydrase inhibitor dorzolamide for the treatment of cystoid macular edema, renin inhibitor aliskiren, which is used for essential hypertension, Human immunodeficiency virus (HIV) protease inhibitors saquinavir, ritonavir, and indinavir for the treatment of HIV. Moreover, the CADD and bioinformatics tools provide benefits such as cost-saving, time to market, in-sight knowledge of drug-receptor interactions, and speed up drug discovery and development. Such advantages offered by drug modeling software for drug discovery and drug development will drive the segmental growth during the forecast period.

Additionally, the development of new platforms will further offer lucrative opportunities. For instance, on  March 16, 2020, Fujitsu has partnered with Polarisqb to pilot a ground-breaking new drug discovery platform designed to support pharmaceutical companies in bringing vital medication to market quickly and cost-effectively. The platform uses quantum-inspired technology, machine learning, hybrid quantum mechanics, and molecular mechanics simulations (QM/MM) to transform the process of drug discovery. On July 19, 2019, Pumas-AI, a new company established by the University of Maryland School of Pharmacy faculty members, announced its first cutting-edge software platform for pharmaceutical researchers and clinicians,  known as Pharmaceutical Modeling and Simulation (Pumas). It is a comprehensive platform based on the Julia programming language that contains multiple modules designed to meet the needs of analysts in the pharmaceutical industry, while also working to advance therapeutic innovation in the clinic setting. In August 2019, London, UK-headquartered Evaluate, a company providing software services for researchers and drug developers, has released Product Specific PTRS (probability of technical and regulatory success), a platform that processes data to predict a drug's likelihood of success. However, the predictive analysis of drug targets segment is anticipated to witness a significant growth rate during the forecast period

The prominent/emerging players in the Drug Modeling Software Market research include:

Axtria, Inc.
Avalon Health Economics LLC
MEDLIOR
PHARMALEX GMBH
Analysis Group
ICON PLC
IQVIA Inc.
McKESSON CORPORATION
Syneos Health
Optum, Inc.

Company overview:

Company overview provides the information about location of the company where it is headquartered along with the established year, employee strength as of 2017, regions where the company is operating and the key business areas.

Financial performance:

Overall company/segment revenue for the year 2019, 2018, and 2017 is provided in the sub title "financial performance" (public listed companies) along with the analysis and explanation of the increase or decrease in the same due to factors such as mergers & acquisition, profit or loss in any strategic business unit (sbus) and others.

Product benchmarking:

Product benchmarking comprises the comprehensive list of products pertaining to the respective market along with the application and key features.

Strategic initiatives:

Insights pertaining to the new product launch, strategic collaboration, mergers and acquisition, regulatory approval, and other developments by the company in market are covered under strategic initiatives section.

Contact us:                                                                                                         

If you have any queries about this report or would like further information, please contact us:

North america:          +1 646 491 9876                                          

Asia-pacific:               +91 20 6727 8686                                         

Email:                         sales@theinsightpartners.com

About us:                                                           

The insight partners is a one stop Market research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as semiconductor and electronics, aerospace and defense, automotive and transportation, Drug Modeling Software, healthcare it, manufacturing and construction, medical device, technology, media and telecommunications, chemicals and materials.

Our research model is very simple. We believe in client servicing and delivering best quality to our customers. Through our research content, we are making sure that our customers get value of their money along with better quality data and analysis.

Our research content is majorly focused towards market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis etc. We provide detailed break-up of segmentation in terms of geography, technology, product and services etc.; which helps our clients to get a deeper analysis on various research topics.

This release was published on openPR.